

# Development of peripheral cannabinoid 1 receptor antagonists targeting diabetes and metabolic disease using AI/CADD-based technology

Sungkyunkwan University



METABOLIC	Lead
Product Type	Small molecule
Indication	1st indication : Diabetes, Metabolic disease 2nd indication : NASH
Target	Cannabinoid receptor 1 (CB1)
MoA(Mechanism of Action)	Inhibition of Peripheral CB1 receptor → Reduction in the pro-inflammatory responses (ROS, ER stress, the NLRP inflammasome activity etc.) in insulin-target tissues including pancreas, adipose tissue, liver → Improvement of obesity-induced insulin resistance and metabolic inflammation
Competitiveness	<ul style="list-style-type: none"> <li>• High affinity and peripheral restricted CB1 receptor antagonist</li> <li>• Low brain level CB1 receptor antagonist may represent a safer alternative to highly brain-penetrant CB1 antagonist</li> <li>• Improved associated lipid and glycemic risk factors in a diet-induced model</li> </ul>
Development Stage	Lead
Route of Administration	Per Oral